MAPT and Alzheimer disease: With the exception of classic and core biomarkers such as Aβ and tau for diagnosing AD, several new biomarkers for AD pathogenesis have been identified in the past decade.[32] These biomarkers can provide higher diagnostic and prognostic accuracy in research cohorts and better understand the changes in neuropathology during development.